Evidence map›Paper›PMID 32957706›Full record

ArticleToxins2020

Structural and Biochemical Characterization of Botulinum Neurotoxin Subtype B2 Binding to Its Receptors.

Jonathan R Davies, Geoffrey Masuyer, Pål Stenmark

Abstract read
In one paragraph

Article in Toxins, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jonathan R DaviesDepartment of Biochemistry and Biophysics, Stockholm University, SE-106 91 Stockholm, Sweden.ORCID 0000-0002-4986-8594
Geoffrey MasuyerDepartment of Biochemistry and Biophysics, Stockholm University, SE-106 91 Stockholm, Sweden.ORCID 0000-0002-9527-2310
Pål StenmarkDepartment of Biochemistry and Biophysics, Stockholm University, SE-106 91 Stockholm, Sweden.ORCID 0000-0003-4777-3417

Funding

Cancerfonden CAN 2017/716Vetenskapsrådet 2018-03406
6 · The paper itself

Abstract

Botulinum neurotoxins (BoNTs) can be used therapeutically to treat a wide range of neuromuscular and neurological conditions. A collection of natural BoNT variants exists which can be classified into serologically distinct serotypes (BoNT/B), and further divided into subtypes (BoNT/B1, B2, …). BoNT subtypes share a high degree of sequence identity within the same serotype yet can display large variation in toxicity. One such example is BoNT/B2, which was isolated from

Indexed as

Binding SitesBotulinum Toxins, Type ACarbohydrate ConformationGangliosidesHydrophobic and Hydrophilic InteractionsProtein BindingProtein ConformationStructure-Activity RelationshipSynaptotagmin IBotulinum Toxins, Type Aganglioside, GD1aGangliosidesrimabotulinumtoxinBSynaptotagmin ISYT1 protein, humanBoNT/Bbotulinum neurotoxinbotulismClostridium botulinumgangliosidesynaptotagmin

Identifiers

PMID32957706
PMCPMC7551386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.